Free Trial
→ Outperform BTC without owning any crypto? (From ProsperityPub) (Ad)

Adial Pharmaceuticals Q3 2023 Earnings Report

Adial Pharmaceuticals logo
$0.97 +0.01 (+1.30%)
As of 04:00 PM Eastern
Earnings HistoryForecast

Adial Pharmaceuticals EPS Results

Actual EPS
-$1.14
Consensus EPS
-$1.14
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Adial Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Adial Pharmaceuticals Announcement Details

Quarter
Q3 2023
Date
11/14/2023
Time
N/A

Conference Call Resources

Adial Pharmaceuticals Earnings Headlines

Adial Pharmaceuticals files to sell 5.0M shares of common stock for holders
December 21, 2024 | markets.businessinsider.com
Adial granted U.S. patent for treatment of alcohol, drug dependence
December 3, 2024 | markets.businessinsider.com
A simple pattern that works in any market
Right when most traders were getting bearish, The All-Weather Pattern signaled something different. Following this setup could've turned every $1,000 into $1,770 in just 48 hours. But here's what really gets me excited... You don't need to be glued to your screen all day, no complex formulas, no guessing. Just wait for a stock to close below The All-Weather Pattern, then check if it opens higher the next morning. That's it. While of course I cannot promise future returns or against losses… I've put together a complete breakdown of how this works, including the new stock that’s tending towards The All-Weather Pattern this week.
January 21, 2025 | WealthPress (Ad)
EXCLUSIVE: Adial Pharmaceuticals' Lead Drug Secures Key US Patent For Alcohol Dependence Based on Expanded Genotype Combinations
December 3, 2024 | finance.yahoo.com
Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations
December 3, 2024 | globenewswire.com
Adial Pharmaceuticals Advances AD04 with Promising Study Results
November 19, 2024 | markets.businessinsider.com
See More Adial Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Adial Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adial Pharmaceuticals and other key companies, straight to your email.

About Adial Pharmaceuticals

Adial Pharmaceuticals (NASDAQ:ADIL), a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

View Adial Pharmaceuticals Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles